Addex Pharmaceuticals / Addex to Present at The New York Academy of Sciences  est traité et transmis par Hugin AS. L''émetteur est uniquement responsable du contenu de ce communiqué de presse. 


          Data on Promising Clinical-Stage Parkinson's Disease Product
                   Addex Discovery Capabilities Illustrated

Geneva,  Switzerland, 17 February  2010 - Addex  Pharmaceuticals (SIX:ADXN), the
allosteric  modulation company, announced  today that it  will participate at an
event  hosted  by  The  New  York  Academy  of  Sciences entitled, "Metabotropic
Glutamate  Receptors:  Translation  from  Discovery  to  Clinical  Trials."  Dr.
Jean-Philippe  Rocher,  head  of  core  chemistry  at  Addex,  will  discuss the
discovery  and development of ADX48621 in a talk entitled: "Discovery of a Novel
Series  of  Selective  mGluR5  Negative  Allosteric  Modulators."  ADX48621  has
completed  Phase  I  clinical  development  and  is  scheduled to start Phase II
testing in the fourth quarter of 2010.

Metabotropic glutamate receptors were first described in 1987 and cloned in the
early '90s.  Today they are considered the single most promising new collection
of targets for CNS drug discovery, with therapeutic potential to treat illnesses
ranging from migraine to esophageal reflux, and from schizophrenia to
Parkinson's disease.

The symposium, to be held at the New York Academy of Sciences conference center
in New York City on February 23, 2010, from 1:00 pm - 5:00 pm, brings together
national and international experts from academia and industry to present
research spanning intramolecular signal transduction, regulation, pharmacology,
their role in motor function, and the therapeutic use.

For more information about the event please visit:
http://www.nyas.org/metabotropic

The  New York Academy of Sciences is an independent, not-for-profit organization
committed  to advancing science, technology,  and society worldwide since 1817.
With  24,000 members in  140 countries, NYAS  is creating  a global community of
science for the benefit of humanity. NYAS' core mission is to advance scientific
knowledge,  positively  impact  the  major  global  challenges  of  society with
science-based  solutions,  and  increase  the  number of scientifically informed
individuals in society at large.

Investors and media interested to attend please contact:

Adrienne Burke
Director, Public Outreach
The New York Academy of Science
250 Greenwich St., 40th floor
New York, NY 10007
+1 (212) 298-8655
aburke@nyas.org 


Addex    Pharmaceuticals   (www.addexpharma.com   <http://www.addexpharma.com/>)
utilizes  its unique proprietary  platform technologies to  discover and develop
allosteric  modulators for human  health. Allosteric modulators  are a different
kind of orally available small molecule therapeutic agent, which we believe will
offer  a  competitive  advantage  over  classical  drugs.  With  15 programs  in
development,   the  Addex  pipeline  demonstrates  the  productivity  and  broad
potential  of our unparalleled platform technologies. The most advanced product,
ADX48621,  an mGluR5 negative allosteric modulator  (NAM), has completed Phase I
testing  and  is  scheduled  to  start  Phase II testing for Parkinson's disease
levodopa associated dyskinesia (PD-LID) later this year.
Our  products  and  technology  already  have  proven  their  value  through our
relationships  with four  of the  top10 pharmaceutical  companies in  the world.
Specifically,  under an  agreement with  Ortho-McNeil-Janssen Inc.,  a Johnson &
Johnson  company, ADX71149,  an mGluR2  positive allosteric  modulator (PAM), is
undergoing  Phase  I  clinical  testing  and  has  potential  for  treatment  of
schizophrenia and anxiety. Under two separate agreements with Merck & Co., Inc.,
we  are  developing  PAMs  of  mGluR4  and  mGluR5 as drugs to treat Parkinson's
disease  and  schizophrenia,  respectively.  In  addition, SR-One, the corporate
venture  arm  of  GlaxoSmithKline,  and  Roche  Venture  Fund  have  made equity
investments in Addex.

Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos@addexpharma.com 


Disclaimer: The foregoing release contains forward-looking statements that can
be identified by terminology such as "not approvable", "continue", "believes",
"believe", "will", "remained open to exploring", "would", "could", or similar
expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results with
allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic targets to
be materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee that
allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in
any market or by any regulatory authority. Nor can there be any guarantee
that allosteric modulators of mGluR4, mGluR2, mGluR5 or other therapeutic
targets will achieve any particular levels of revenue (if any) in the future. In
particular, management's expectations regarding  allosteric modulators of
mGluR4, mGluR2, mGluR5 or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Pharmaceuticals is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.


[HUG#1385505]



 --- Fin de Message --- 

Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Schweiz

ISIN: CH0029850754;